Accuracy of administrative claims prescription fill data to estimate glucocorticoid use and dose in patients with rheumatoid arthritis

摘要

Abstract Purpose To assess accuracy of administrative claims prescription fill‐based estimates of glucocorticoid use and dose, and approximate bias from glucocorticoid exposure misclassification. Methods We identified adults with rheumatoid arthritis with linked Medicare and CorEvitas registry data. An algorithm identifying glucocorticoid use and average dose over 90?days from Medicare prescription fills was compared to physician‐reported measures from a CorEvitas visit during the same period, using weighted kappa to compare doses (none, ≤5?mg, 5–10?mg, >10?mg/day). A deterministic sensitivity analysis examined the effect of exposure misclassification on estimated glucocorticoid‐associated infection risk from a prior study. Results We identified 621 observations among 494 patients. Prescription fills identified glucocorticoid use in 41.9 of observations versus 31.1 identified by CorEvitas physician‐report. For glucocorticoid use (yes/no), prescription fills had sensitivity 88.1 (95 CI 82.7–92.3), specificity 79.0 (74.8–82.7), PPV 65.4 (59.3–71.2), NPV 93.6 (90.6–95.9), and 81.8 agreement with CorEvitas, with kappa 0.61 (moderate to substantial agreement). There was 89.5 agreement between prescription fills and physician‐reported doses, with weighted kappa 0.56 (moderate agreement). Applying these results to a prior Medicare study evaluating glucocorticoid‐associated infection risk risk ratio 1.44 (95 CI 1.41–1.48) led to an externally adjusted risk ratio of 1.74 when accounting for exposure misclassification, representing ?17 bias in infection risk estimate. Conclusions This study supports the use of claims data to estimate glucocorticoid use and dose, but investigators should account for exposure misclassification, which may lead to underestimates of glucocorticoid risks. Our results could be applied to adjust risk estimates in other studies that use prescription fills to estimate glucocorticoid use.